Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Total Current Liabilities

All obligations due within one year.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026

Total current liabilities rises 44.7% from a year ago

Total current liabilities stood at $150.89M at the end of Q3 FY2026, up 44.7% from a year earlier and up 22.1% from the prior quarter. Over 3 fiscal years it compounded at +38.6% a year.

Context

  • Total current liabilities amounted to 34.1% of total assets at the end of Q3 FY2026, up 13.5 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +44.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$150.89M+22.1% QoQ
Last fiscal yearDec 2025
$105.94M-8.3% YoY
Year agoSep 2025
$104.27M+44.7% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.7%——
1 year-8.3%——
3-year CAGR+38.6%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
105.94M USD
Year-over-year change
-8.3%
4-year CAGR
+25.0%

Total Current Liabilities vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's Sep 2026 total current liabilities of $150.89M is the 2nd highest of the 11 companies compared; the peer median is $23.2M.
  • Its year-over-year change of +44.7% is the 5th highest of 10, against a peer median of +39.3%.
  • Total current liabilities amounts to 34.1% of total assets for RYTM, versus a peer median of 9.5%.
RYTM Competitors Peer median
Total Current Liabilities for RYTM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMRNBioMarin Pharmaceutical Inc.Sep 2026$1.6T +200895.4%+8.8%13.9%
RYTMRhythm Pharmaceuticals, Inc.Sep 2026$150.89M +44.7%+38.6%34.1%
VKTXViking Therapeutics, Inc.Jun 2026$109.66M +242.9%+51.7%21.0%
SEPNSepterna, Inc.Sep 2026$104.86M +39.3%+150.3%16.9%
GPCRStructure Therapeutics Inc.Jun 2026$66.11M +69.4%+69.4%4.6%
MBXMBX Biosciences, Inc. Common StockSep 2026$25.17M +108.6%+65.3%5.0%
MAZEMaze Therapeutics, Inc.Mar 2026$21.24M +14.1%+2.8%5.1%
BIOABioAge Labs, Inc.Mar 2026$15.83M -33.3%+50.9%4.0%
BLTEBelite Bio, IncJun 2026$14.95M —+67.5%1.9%
BMEABiomea Fusion, Inc.Mar 2026$9.29M -53.1%-16.5%20.0%
PTNPalatin Technologies, Inc.Mar 2026$2.54M -74.8%-21.0%19.2%
Peer median (excluding RYTM) $23.2M+39.3%+51.3%9.5%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents59.25M127.68M60.08M89.14M54.3M
Short-term Investments235.61M205.61M215.77M231.43M334.65M
Net Receivables1.03M6.22M14.87M18.51M26.08M
Inventory111K2.92M8.62M18.74M25.75M
Other Current Assets3.99M7.42M6.67M8.8M9.97M
Total Current Assets308.39M354.24M308.27M374.2M466.92M
Property, Plant & Equipment (Net)4.34M3.38M2.12M4.11M4.15M
Goodwill00000
Intangible Assets4.66M7.88M7.03M6.17M5.32M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets12.14M16.98M15.33M7.79M3.81M
Total Non-current Assets21.14M28.25M24.48M18.07M13.28M
Total Assets329.52M382.48M332.75M392.27M480.2M
Account Payables5.74M4.8M4.89M12.33M13.95M
Short-term Debt00000
Tax Payables00000
Deferred Revenue7M1.43M1.29M1.29M194K
Other Current Liabilities800K2.42M5.41M43.6M11.37M
Total Current Liabilities43.43M39.81M55.2M115.52M105.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities077.15M107.29M108.27M100.89M
Total Non-current Liabilities1.95M78.41M107.78M112.21M104.23M
Total Liabilities45.37M118.22M162.99M227.72M210.17M
Common Stock50K56K59K61K67K
Retained Earnings(528.94M)(710.06M)(894.74M)(1.16B)(1.35B)
Accumulated OCI(1K)(92K)134K(39K)(796K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity284.15M264.26M169.76M164.55M270.03M
Total Debt2.55M1.94M1.26M3.94M3.99M
Net Debt(56.7M)(125.73M)(58.82M)(85.2M)(50.31M)

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.